The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China


On March 28, 2023, Kylo-0603, a thyroxine receptor-β (THR-β) agonist drug independently developed by Shanghai Hegia Biomedicine Co., Ltd. for the indication of non-alcoholic steatohepatitis (NASH), successfully completed the first human administration of phase I clinical trial in the First Affiliated Hospital of Zhejiang University School of Medicine.

The study (CTR20230472) is a Phase I dose-climbing clinical study of single and multiple administration in healthy subjects. The primary objective was to evaluate the pharmacokinetic (PK) characteristics, safety and tolerability, and food effects of single and multiple administration of Kylo-0603 in healthy Chinese subjects to support subsequent clinical development of Kylo-0603 in indications such as non-alcoholic steatohepatitis (NASH).